SEFH

  • Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection. Mark S. Sulkowski, David F. Gardiner, Maribel Rodriguez-Torres et al. N Engl J Med 2014; 370 (3): 211-221. Descargar pdf
  • Phase 2b Trial of Interferon-free Therapy for Hepatitis C Virus Genotype 1. Kris V. Kowdley, Eric Lawitz, Fred Poordad et al.N Engl J Med 2014; 370 (3), 2014. Descargar pdf
  • Sofosbuvir/velpatasvir: a promising combination. Aldo Bonaventura, Fabrizio Montecucco. World J Hepatol. 2016; 8(19): 785-789. Descargar pdf
  • Comparison of the effectiveness and renal safety of tenofovir versus entecavir in patients with chronic hepatitis B. Beatriz López Centeno et al. Farm Hosp. 2016;40(4) :279-286. Descargar pdf
  • Comparative effectiveness of ledipasvir/sofosbuvir ribavirin vs. ombitasvir/paritaprevir/ritonavir + dasabuvir ribavirin in 6961 genotype 1 patients treated in routine medical practice. Backus, L. I., Belperio, P. S., Shahoumian, T. A., Loomis, T. P. and Mole, L. A. . Aliment Pharmacol Ther 2016; 44: 400–410. Descargar pdf
  • Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients with HCV Genotype 2, 3, 4, or 6 Infections in an Open-label, Phase 2 Trial. Gane, Edward et al. Gastroenterology. Descargar pdf